NovoCure Financial Results
Novocure reported record third-quarter net revenues of $193.4 million, a 16% year-over-year increase driven by 19% growth in active patients. The company significantly narrowed its net loss to $10.4 million and raised its full-year 2026 revenue and adjusted EBITDA guidance based on strong commercial performance.
- Term
- Q3 2026
“Novocure’s strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies.”
Frank Leonard, CEO, Novocure
“We achieved record-high quarterly net revenue and are well-positioned to achieve the commercial, clinical and financial goals we set out in January. Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability.”
Frank Leonard, CEO, Novocure